Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial. Platzbecker AS, Georgi JA, Middeke JM, Sockel K, et al. Blood 2026;147:1098-1110.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Platzbecker AS, Georgi JA, Middeke JM, Sockel K, et al. Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial. Blood 2026;147:1098-1110.
PMID: 41359791